Skip to main content
Premium Trial:

Request an Annual Quote

Nanosyn to Provide Screening, Profiling Services to Forma Therapeutics

NEW YORK (GenomeWeb) – Contract research organization Nanosyn today announced a multiyear research service agreement to provide its microfluidics screening and profiling capabilities to Forma Therapeutics.

Nanosyn will provide to Forma its lab-on-a-chip biology services, which comprises more than 500 mobility shift assays. Forma will have access to Nanosyn's screening and profiling services and fragment-based screening drug discovery platform.

Nanosyn will also develop novel assays in support of Forma's epigenetic and protein homeostasis programs, including screening against Forma's and Nanosyn's proprietary chemical libraries, while Forma will support biological and medicinal chemistry activities at Nanosyn for Forma's hit-to-lead and lead optimization programs, Nanosyn said.

Financial and other terms of the deal were not disclosed.

Nanosyn is based in Santa Clara, Calif., and provides assay development, screening and profiling services, integrated drug discovery and development services, and other capabilities.

Filed under

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.